Erste Asset Management GmbH Acquires 124 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Erste Asset Management GmbH raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 41,487 shares of the medical equipment provider’s stock after buying an additional 124 shares during the period. Erste Asset Management GmbH’s holdings in Zimmer Biomet were worth $4,434,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Atria Investments Inc grew its position in shares of Zimmer Biomet by 60.2% during the 3rd quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider’s stock worth $586,000 after buying an additional 2,041 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter worth $28,000. Oppenheimer & Co. Inc. grew its position in shares of Zimmer Biomet by 8.6% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 24,995 shares of the medical equipment provider’s stock worth $2,698,000 after buying an additional 1,977 shares in the last quarter. KBC Group NV grew its position in shares of Zimmer Biomet by 64.0% during the 3rd quarter. KBC Group NV now owns 25,287 shares of the medical equipment provider’s stock worth $2,730,000 after buying an additional 9,864 shares in the last quarter. Finally, Metis Global Partners LLC grew its position in shares of Zimmer Biomet by 6.0% during the 3rd quarter. Metis Global Partners LLC now owns 11,885 shares of the medical equipment provider’s stock worth $1,283,000 after buying an additional 671 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 2.4 %

Shares of NYSE:ZBH opened at $110.10 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock has a market cap of $21.92 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.95 and a beta of 1.04. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $105.83 and a 200-day moving average price of $107.03.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company earned $2.20 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s payout ratio is currently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial reaffirmed a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.